Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%

被引：10

作者：

Zarogoulidis, Paul ^{[1
]}

Papadopoulos, Vasilis ^{[2
]}

Maragouli, Elena ^{[2
]}

Papatsibas, George ^{[2
]}

Sardeli, Chrysanthi ^{[3
]}

Man, Yan-Gao ^{[4
]}

Bai, Chong ^{[5
]}

Huang, Haidong ^{[5
]}

机构：

[1] Theageneio Canc Hosp, Pulm Dept, Oncol Unit, Thessaloniki, Greece

[2] Univ Thessaly, Dept Oncol, Larisa, Greece

[3] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Pharmacol & Clin Pharmacol, Thessaloniki, Greece

[4] Vet Affair Hlth Syst, Lab Prote & Prot Sci, Baltimore, MD USA

[5] Second Mil Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai 200000, Peoples R China

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷

关键词：

SMALL BIOPSY; CASE SERIES; STAGE IV; EXPRESSION; SPECIMENS; THERAPY; SAMPLES; UPDATE;

D O I：

10.21037/tlcr.2018.01.04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S28 / S30

页数：3

共 50 条

[21] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
Cronin-Fenton, D.
Dalvi, T.
Hedgeman, E.
Norgaard, M.
Petersen, L.
Hansen, H.
Fryzek, J.
Lawrence, D.
Walker, J.
Mellemgaard, A.
Rasmussen, T.
Shire, N.
Rigas, J.
Potter, D.
Hamilton-Dutoit, S.
Sorensen, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
[22] First-line treatment for non-small cell lung cancer
Pinn, Stephen
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
[23] A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%
Clugston, D. M.
Beck, C.
Bjerregaard, B. K.
Kristensen, E. S.
VALUE IN HEALTH, 2023, 26 (12) : S514 - S514
[24] PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
Majem, Margarita
Cobo, Manuel
Isla, Dolores
Marquez-Medina, Diego
Rodriguez-Abreu, Delvys
Casal Rubio, Joaquin
Moran Bueno, Teresa
Bernabe Caro, Reyes
Perez Parente, Diego
Ruiz Gracia, Pedro
Marina Arroyo, Marta
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
Masago, Katsuhiro
Fujita, Shiro
Hata, Akito
Okuda, Chiyuki
Kaji, Reiko
Katakami, Nobuyuki
Hirata, Yukio
ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
[26] PD-L1 heterogeneity in patients with non-small cell lung cancer
Wei, Zhigang
Fan, Linlin
Yang, Xia
Li, Jie
Zhan, Xuemei
Ye, Xin
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
[27] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
Jotatsu, Takanobu
Oda, Keishi
Yatera, Kazuhiro
JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
[28] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
La-Beck, Ninh M.
Nguyen, Dung T.
Le, Alex D.
Alzghari, Saeed K.
Trinh, Saralinh T.
PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
[29] A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
Fu, Jie
Yan, Yi-Dan
Wan, Xu
Sun, Xiao-Fan
Ma, Xiu-Mei
Su, Ying-Jie
FRONTIERS IN PHARMACOLOGY, 2025, 15
[30] Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Ikeda, Mio
Koh, Yasuhiro
Teraoka, Shunsuke
Sato, Koichi
Oyanagi, Jun
Hayata, Atsushi
Tokudome, Nahomi
Akamatsu, Hiroaki
Ozawa, Yuichi
Endo, Katsuya
Higuchi, Masayuki
Nakanishi, Masanori
Ueda, Hiroki
Yamamoto, Nobuyuki
CANCERS, 2021, 13 (10)

← 1 2 3 4 5 →